Sign In
Buy QGEN
$37.56
+1.11 (+3.05%)
At Close: Jun 04, 2026
GERMANTOWN, Maryland & HILDEN, Germany--(BUSINESS WIRE)---- $QGEN--QIAGEN receives U.S. FDA emergency use authorization for rapid portable test that can analyze over 30 samples per hour for SARS-CoV-2
QIAGEN (QGEN) Q2 Earnings Top Estimates, Margins Decline
12:10pm, Friday, 30'th Jul 2021
Faster-than-expected vaccination uptake leads to a reduction in demand for COVID-19 testing for QIAGEN (QGEN) in Q2.
Qiagen Stock gains As Non COVID Sales Boosts Q2 Topline, Bottom-line
08:26am, Friday, 30'th Jul 2021
Qiagen N.V. (NYSE: QGEN) reported after the close of the market Thursday that its second-quarter revenues jumped 28% Y/Y as growth in its core product portfolio tempered, flagging non-COVID-19-rela
Qiagen (QGEN) Beats Q2 Earnings and Revenue Estimates
09:17pm, Thursday, 29'th Jul 2021
Qiagen (QGEN) delivered earnings and revenue surprises of 1.52% and 0.88%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Qiagen Stock Drops After Trimming FY21 Earnings Forecast On Weaker COVID-19 Testing Trends
12:53pm, Monday, 12'th Jul 2021
Qiagen NV (NYSE: QGEN) has reported higher-than-expected second-quarter interim earnings but lowered its outlook on weaker demand for COVID-19 tests, sending its shares lower. The company expects Q
Qiagen cuts outlook on weaker COVID-19 testing trends, shares fall
12:17pm, Monday, 12'th Jul 2021
U.S.-German genetic testing company Qiagen NV reported higher-than-expected second-quarter earnings on Monday but lowered its outlook on weaker demand for COVID-19 tests, sending its shares lower in N
QIAGEN N.V. Conference Call on July 13 to Discuss Preliminary Q2 2021 Results
11:55am, Monday, 12'th Jul 2021
VENLO, the Netherlands--(BUSINESS WIRE)--QIAGEN N.V. conference call on July 13 to discuss preliminary Q2 2021 results
Qiagen stock reverses lower after upbeat Q2 outlook, but downbeat Q3 view
11:40am, Monday, 12'th Jul 2021
Shares of Qiagen N.V. slumped 4.5% in morning trading Monday, reversing an earlier intraday gain of as much 1.7%, after the Netherlands-based biotechnology company provided an upbeat second-quarter re
VENLO, the Netherlands--(BUSINESS WIRE)---- $QGEN #earnings--QIAGEN announces preliminary Q2 2021 results exceeding outlook, updates full-year 2021 outlook
QIAGEN's (QGEN) NeuMoDx HAdV Quant Assay Wins CE-IVD Mark
12:57am, Sunday, 11'th Jul 2021
QIAGEN's (QGEN) NeuMoDx solutions at present offer CE-IVD tests for various viral and bacterial pathogens.
QIAGEN's (QGEN) NeuMoDx HAdV Quant Assay Wins CE-IVD Mark
08:16am, Friday, 09'th Jul 2021
QIAGEN's (QGEN) NeuMoDx solutions at present offer CE-IVD tests for various viral and bacterial pathogens.
QIAGEN's NeuMoDx™ HAdV Quant Assay Secures CE-IVD Certification for Automated Testing to Detect Human Adenovirus Infections
04:22pm, Thursday, 08'th Jul 2021
GERMANTOWN, Md. & HILDEN, Germany--(BUSINESS WIRE)---- $QGEN #adenovirus--QIAGEN's NeuMoDx™ HAdV Quant Assay secures CE-IVD certification for automated testing to detect human adenovirus infections
QIAGEN (QGEN) Faces COVID-Support Sales Drop, Huge Debt
09:46am, Wednesday, 07'th Jul 2021
With gradually falling COVID-19 cases, since the beginning of 2021, QIAGEN's (QGEN) COVID-19 testing related product lines are seeing significant decline in sales.
QIAGEN (QGEN), Sysmex Ink Cancer Companion Diagnostics Deal
09:01am, Monday, 05'th Jul 2021
QIAGEN (QGEN) and Sysmex collaborate to develop and commercialize cancer companion diagnostics.
HILDEN, Germany & GERMANTOWN, Md. & KOBE, Japan--(BUSINESS WIRE)---- $QGEN #cdx--QIAGEN forms strategic alliance with Sysmex Corporation for global cancer companion diagnostics development and commerc
